| [1] |
Beauchemin N,Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis[J]. Cancer and Metastasis Reviews, 2013, 32(3-4): 643-671.
|
| [2] |
Dupuis ML,Fiori V,Soriani A, et al. The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro[J]. J immunother, 2015, 38(9): 357-370.
|
| [3] |
Ling Y,Wang J,Wang L, et al. Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases[J]. Cancer and Metastasis Rev, 2015, 34(2): 347-357.
|
| [4] |
Zippel D,Barlev H,Ortenberg R, et al. A longitudinal study of CEACAM1 expression in melanoma disease progression[J]. Oncol Rep, 2015, 33(3): 1314-1318.
|
| [5] |
Lu R,Kujawski M,Pan H, et al. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1[J]. Cancer Res, 2012, 72(9): 2239-2250.
|
| [6] |
Gebauer F,Wicklein D,Horst J, et al. Carcinoembryonic Antigen-Related Cell Adhesion Molecules (CEACAM) 1, 5 and 6 as Biomarkers in Pancreatic Cancer[J]. Plos One, 2014, 9(11): e113023.
|
| [7] |
Duxbury MS. CEACAM1 Cytoplastic Expression Is Closely Related to Tumor Angiogenesis and Poorer Relapse-free Survival After Curative Resection of Hepatocellular Carcinoma[J]. World J Surg, 2011, 35(10): 2266-2267.
|
| [8] |
Berardi R,Morgese F,Onofri A, et al. Role of maspin in cancer[J]. Clin Transl Med, 2013, 2(1): 8.
|
| [9] |
Chen CJ,Kirshner J,Sherman MA, et al. Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation[J]. J Biol Chem, 2007, 282(8): 5749-5760.
|
| [10] |
Gaur S,Shively JE,Yen Y, et al. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms[J]. Mol Cancer, 2008, 7(5): 46.
|
| [11] |
Müller MM,Klaile E,Vorontsova O, et al. Homophilic adhesion and CEACAM1-S regulate dimerization of CEACAM1-L and recruitment of SHP-2 and c-Src[J]. J cell Biol, 2009, 187(4): 569-581.
|
| [12] |
Morales VM,Christ A,Watt SM, et al. Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a)[J]. J Immunol, 1999, 163(3): 1363-1370.
|
| [13] |
Boulton IC,Gray-Owen SD. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes[J]. Nat immunol, 2002, 3(3): 229-236.
|
| [14] |
Markel G,Mussaffi H,Ling KL, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients[J]. Blood, 2004, 103(5): 1770-1778.
|
| [15] |
Markel G,Seidman R,Stern N, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions[J]. J Immunol, 2006, 177(9): 6062-6071.
|
| [16] |
Chen L,Chen Z,Baker K, et al. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction[J]. Immunity, 2012, 37(5): 930-946.
|
| [17] |
Chen D,Iijima H,Nagaishi T, et al. Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function[J]. J Immunol, 2004, 172(6): 3535-3543.
|
| [18] |
Chen Z,Chen L,Qiao SW, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70[J]. J Immunol, 2008, 180(9): 6085-6093.
|
| [19] |
Nagaishi T,Pao L,Lin SH, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms[J]. Immunity, 2006, 25(5): 769-781.
|
| [20] |
Ling Y,Wang J,Wang L, et al. Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases[J]. Cancer and Metastasis Rev, 2015, 34(2): 347-357.
|
| [21] |
Huang YH,Zhu C,Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion[J]. Nature, 2015, 517(7534): 386-390.
|
| [22] |
Markel G,Ortenberg R,Seidman R, et al. Systemic dysregulation of CEACAM1 in melanoma patients[J]. Cancer immunol immunother, 2010, 59(2): 215-230.
|
| [23] |
Ullrich N,Heinemann A,Nilewski E, et al. CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survival[J]. Cancer Res, 2015, 75(9): 1897-1907.
|
| [24] |
Kammerer R,Riesenberg R,Weiler C, et al. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma[J]. J pathol, 2004, 204(3): 258-267.
|
| [25] |
Hosomi S,Chen Z,Baker K, et al. CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling[J]. Eur J Immunol, 2013, 43(9): 2473-2483.
|
| [26] |
Ullrich N,Heinemann A,Nilewski E, et al. CEACAM1-3S drives melanoma cells into NK cell-mediated cytolysis and enhances patient survival[J]. Cancer Res, 2015, 75(9): 1897-1907.
|
| [27] |
Satoh Y,Hayashi T,Takahashi T, et al. Expression of CD66a in multiple myeloma[J]. J Clin Lab Anal, 2002, 16(2): 79-85.
|
| [28] |
Skubitz KM,Ducker TP,Goueli SA. CD66 monoclonal antibodies recognize a phosphotyrosine-containing protein bearing a carcinoembryonic antigen cross-reacting antigen on the surface of human neutrophils[J]. J Immunol, 1992, 148(3): 852-860.
|
| [29] |
Botling J,Oberg F,Nilsson K. CD49f (alpha 6 integrin) and CD66a (BGP) are specifically induced by retinoids during human monocytic differentiation[J]. Leukemia, 1995, 9(12): 2034-2041.
|
| [30] |
Pan H,Shively JE. Carcinoembryonic antigen-related cell adhesion molecule-1 regulates granulopoiesis by inhibition of granulocyte colony-stimulating factor receptor[J]. Immunity, 2010, 33(4): 620-631.
|
| [31] |
Huang J,Ledford KJ,Pitkin WB, et al. Targeted Deletion of Murine CEACAM 1 Activates PI3K-Akt Signaling and Contributes to the Expression of (Pro) Renin Receptor via CREB Family and NF-κB Transcription Factors[J]. Hypertension, 2013, 62(2): 317-323.
|
| [32] |
Nonaka M,Ma BY,Murai R, et al. Glycosylation-dependent interactions of C-type lectin DC-SIGN with colorectal tumor-associated Lewis glycans impair the function and differentiation of monocyte-derived dendritic cells[J]. J Immunol, 2008, 180(5): 3347-3356.
|
| [33] |
Ortenberg R,Sapir Y,Raz L, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions[J]. Mol Cancer Ther, 2012, 11(6): 1300-1310.
|
| [34] |
Sivan S,Ohad H,Rona O, et al. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms[J]. Clin Dev Immunol, 2012, 2012(4):399-408.
|
| [35] |
Inhibiting CTLA-4 and PD-1 boosts response[J]. Cancer discovery, 2013, 3(7): 710-711.
|
| [36] |
Liu J,Di G,Wu CT, et al. Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5[J]. Biochem Biophys Res Commun, 2013, 432(2): 370-377.
|
| [37] |
Zheng C,Feng J,Lu D, et al. A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity[J]. PloS one, 2011, 6(6): e21146.
|